相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron
M. V. Tzvetkov et al.
PHARMACOGENOMICS JOURNAL (2012)
BDDCS Applied to Over 900 Drugs
Leslie Z. Benet et al.
AAPS JOURNAL (2011)
Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution
Jeffrey A. Pfefferkorn et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
A Common 5′-UTR Variant in MATE2-K Is Associated With Poor Response to Metformin
J. H. Choi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Targeting Intestinal Transporters for Optimizing Oral Drug Absorption
Manthena V. Varma et al.
CURRENT DRUG METABOLISM (2011)
Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response
Alice C. Rodrigues et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2011)
Cerivastatin, genetic variants, and the risk of rhabdomyolysis
Kristin D. Marciante et al.
PHARMACOGENETICS AND GENOMICS (2011)
The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c
Mette M. H. Christensen et al.
PHARMACOGENETICS AND GENOMICS (2011)
Pharmacogenetics of drug transporters in the enterohepatic circulation
Bruno Stieger et al.
PHARMACOGENOMICS (2011)
Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms
Mladen V. Tzvetkov et al.
PHARMACOGENOMICS (2011)
Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake
Mikko Niemi et al.
PHARMACOLOGICAL REVIEWS (2011)
Why It Is Time to Sequence Response
Jon McClellan et al.
CELL (2010)
The Role of Organic Anion-Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics
N. Picard et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
P-glycoprotein related drug interactions: clinical importance and a consideration of disease states
Caroline A. Lee et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Oral Sulfasalazine as a Clinical BCRP Probe Substrate: Pharmacokinetic Effects of Genetic Variation (C421A) and Pantoprazole Coadministration
Kimberly K. Adkison et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Genetic Polymorphisms in Organic Cation Transporter 1 (OCT1) in Chinese and Japanese Populations Exhibit Altered Function
Ligong Chen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Improved Extrapolation of Hepatobiliary Clearance from in Vitro Sandwich Cultured Rat Hepatocytes through Absolute Quantification of Hepatobiliary Transporters
Na Li et al.
MOLECULAR PHARMACEUTICS (2010)
Membrane transporters in drug development
Kathleen M. Giacomini et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
INFLUENCE OF ABCB1 GENETIC POLYMORPHISMS ON THE PHARMACOKINETICS OF LEVOSULPIRIDE IN HEALTHY SUBJECTS
H. Y. Cho et al.
NEUROSCIENCE (2010)
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response
Matthijs L. Becker et al.
PHARMACOGENETICS AND GENOMICS (2010)
Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients
Kana Toyama et al.
PHARMACOGENETICS AND GENOMICS (2010)
Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability
Richard H. Ho et al.
PHARMACOGENETICS AND GENOMICS (2010)
No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin
Jenni E. Keskitalo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
K. K. Filipski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin
M. V. Tzvetkov et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study
Matth S. L. Becker et al.
DIABETES (2009)
Functional Characterization of the Human Organic Cation Transporter 2 Variant p.270Ala > Ser
Oliver Zolk et al.
DRUG METABOLISM AND DISPOSITION (2009)
In vitro-in vivo Extrapolation of Transporter-mediated Clearance in the Liver and Kidney
Hiroyuki Kusuhara et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs
Ichiro Ieiri et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans
Takao Watanabe et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin
Ying Chen et al.
PHARMACOGENETICS AND GENOMICS (2009)
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simastatin
Jenni E. Keskitalo et al.
PHARMACOGENOMICS (2009)
Meta-Analysis of the Effect of MDR1 C3435T Polymorphism on Cyclosporine Pharmacokinetics
Zhi-Ping Jiang et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2008)
Physiochemical drug properties associated with in vivo toxicological outcomes
Jason D. Hughes et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range
Annikka Kalliokoski et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Postmenopausal hormone therapy for disease prevention: Have we learned any lessons from the past?
J. E. Rossouw
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans
Y. Yamasaki et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin
I. S. Song et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
A ligand-based approach to mining the chemogenomic space of drugs
Elisabet Gregori-Puigjane et al.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2008)
Organic Cation Transporters and their Pharmacokinetic and Pharmacodynamic Consequences
Min-Koo Choi et al.
DRUG METABOLISM AND PHARMACOKINETICS (2008)
Pharmacogenetics:: data, concepts and tools to improve drug discovery and drug treatment
Juergen Brockmoeller et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Breast cancer resistance protein (ABCG2) and drug disposition:: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe
Bradley L. Urquhart et al.
PHARMACOGENETICS AND GENOMICS (2008)
OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine
Zhi-Jun Wang et al.
PHARMACOGENETICS AND GENOMICS (2008)
Global analysis of genetic variation in SLCOIB1
Marja K. Pasanen et al.
PHARMACOGENOMICS (2008)
Polymorphism in human organic cation transporters and metformin action
Hiroshi Takane et al.
PHARMACOGENOMICS (2008)
Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics
Y. Shu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans
J. H. Choi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members
Annick Seithel et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2008)
Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones
Tomohiro Ando et al.
DRUG METABOLISM AND DISPOSITION (2007)
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants
Richard H. Ho et al.
PHARMACOGENETICS AND GENOMICS (2007)
CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population
StuartA Scott et al.
PHARMACOGENOMICS (2007)
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
Yan Shu et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population
Ho-Jin Kang et al.
DRUG METABOLISM AND DISPOSITION (2007)
Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers
Y. Y. Lau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans
Kari T. Kivisto et al.
PHARMACEUTICAL RESEARCH (2007)
A silent polymorphism in the MDR1 gene changes substrate specificity
Chava Kimchi-Sarfaty et al.
SCIENCE (2007)
Variants in the SLCO1B3 gene: Interethnic distribution and association with paclitaxel pharmacokinetics
N. F. Smith et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury
Carmen Lang et al.
PHARMACOGENETICS AND GENOMICS (2007)
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib
George Cusatis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Marja K. Pasanen et al.
PHARMACOGENETICS AND GENOMICS (2006)
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics
Mikko Niemi et al.
PHARMACOGENETICS AND GENOMICS (2006)
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
Ingolf Cascorbi
PHARMACOLOGY & THERAPEUTICS (2006)
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
Mikko Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Genetic variability, haplotype structures, and ethnic diversity of hepatic transporters MDR3 (ABCB4) and bile salt export pump (ABCB11)
Thomas Lang et al.
DRUG METABOLISM AND DISPOSITION (2006)
Effects of organic anion transporting polypeptide IBI haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril
Kazuya Maeda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein
LY Huang et al.
DRUG METABOLISM AND DISPOSITION (2006)
Impact of the SLCOIBI polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin
Michael Igel et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
The human organic anion transporter 3 (OAT3; SLC22A8):: genetic variation and functional genomics
AR Erdman et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2006)
Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics
DA Katz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Searching for polymorphisms that affect gene expression and mRNA processing: Example ABCB1 (MDR1)
Danxin Wang et al.
AAPS JOURNAL (2006)
Expression and function of efflux drug transporters in the intestine
M Takano et al.
PHARMACOLOGY & THERAPEUTICS (2006)
Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants
T Fujita et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
A human transporter protein that mediates the final excretion step for toxic organic cations
M Otsuka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment
M Fiegenbaum et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
E Lee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6)
K Bleasby et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Single nucleotide polymorphisms modify the transporter activity of ABCG2
K Morisaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression
B Chowbay et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Effect of ABCG2 genotype on the oral Bioavailability of topotecan
A Sparreboom et al.
CANCER BIOLOGY & THERAPY (2005)
Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography
L Sasongko et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2)
G Merino et al.
DRUG METABOLISM AND DISPOSITION (2005)
Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics
AD Johnson et al.
PHARMACOLOGY & THERAPEUTICS (2005)
Metformin transport by renal basolateral organic cation transporter hOCT2
N Kimura et al.
PHARMACEUTICAL RESEARCH (2005)
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
M Wadelius et al.
PHARMACOGENOMICS JOURNAL (2005)
Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta
D Kobayashi et al.
DRUG METABOLISM AND DISPOSITION (2005)
Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions
T Sakata et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype
A Sparreboom et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
M Niemi et al.
PHARMACOGENETICS (2004)
Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8)
K Letschert et al.
PHARMACOGENETICS (2004)
Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C)
M Iwai et al.
PHARMACOGENETICS (2004)
Molecular basis of intrahepatic cholestasis
VEH Carlton et al.
ANNALS OF MEDICINE (2004)
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
DW Schneck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Differences in drug pharmacokinetics between east Asians and Caucasians and the role of genetic polymorphisms
K Kim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
J Mwinyi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
LA Doyle et al.
ONCOGENE (2003)
P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement
MVS Varma et al.
PHARMACOLOGICAL RESEARCH (2003)
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes:: Consequences for pravastatin pharmacokinetics
Y Nishizato et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1
Y Shu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Organic anion-transporting polypeptide (OATP) transporter family and drug disposition
RB Kim
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2003)
MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males
T Gerloff et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs
KMM Doan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences
R Kerb et al.
PHARMACOGENETICS (2002)
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin
DS Wang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein
Y Kurata et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function
MK Leabman et al.
PHARMACOGENETICS (2002)
MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects
T Sakaeda et al.
PHARMACEUTICAL RESEARCH (2001)
Polymorphisms in OATP-C -: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans
RG Tirona et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Drug-like properties and the causes of poor solubility and poor permeability
CA Lipinski
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2000)
Functional polymorphisms of the human multidrug-resistance gene:: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
S Hoffmeyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)